Imbruvica receives new indication for cGVHD

Imbruvica (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor developed by Pharmacyclics LLC, has received a further approval in the US – this time to treat adult patients with chronic graft versus host disease (cGVHD).

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States